A review of tumour lysis syndrome with targeted therapies and the role of rasburicase

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 299-326

  Bose, P ^a,d   Qubaiah, O ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

rasburicase; targeted therapies; tumour lysis syndrome; urate oxidase

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALLOPURINOL; BORTEZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DACETUZUMAB; DASATINIB; DEXAMETHASONE; DINACICLIB; FLAVOPIRIDOL; FLUDARABINE; GEMTUZUMAB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; LINTUZUMAB; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NILOTINIB; OBINUTUZUMAB; OBLIMERSEN; RASBURICASE; RITUXIMAB; RO 5072759; SIPLIZUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URICOZYME; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COST BENEFIT ANALYSIS; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPHOMA; MANTLE CELL LYMPHOMA; METASTASIS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; ENZYME THERAPY; HUMANS; HYPERURICEMIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECOMBINANT PROTEINS; RISK FACTORS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 79955748679     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01260.x     Document Type: Review

References (173)

1. Hochberg J, Cairo MS, (2008) Tumor lysis syndrome: current perspective. Haematologica, 93, 9-13. (Pubitemid 351156145)
2. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS, (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of Clinical Oncology, 26, 2767-2778.
3. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ, (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. American Journal of Medicine, 116, 546-554. (Pubitemid 38452647)
4. Navolanic PM, Pui CH, Larson RA, et al. (2003) Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17, 499-514. (Pubitemid 36395643)
5. Baeksgaard L, Sorensen JB, (2003) Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemotherapy and Pharmacology, 51, 187-192. (Pubitemid 36469946)
6. Gemici C, (2006) Tumour lysis syndrome in solid tumours. Clinical Oncology (Royal College of Radiologists (Great Britain)), 18, 773-780. (Pubitemid 44645411)
7. Kalemkerian GP, Darwish B, Varterasian ML, (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. American Journal of Medicine, 103, 363-367. (Pubitemid 27506241)
8. Coiffier B, (2010) Acute tumor lysis syndrome-a rare complication in the treatment of solid tumors. Onkologie, 33, 498-499.
9. Gertz MA, (2010) Managing tumor lysis syndrome in 2010. Leukaemia & Lymphoma, 51, 179-180.
10. Cairo MS, Bishop M, (2004) Tumour lysis syndrome: new therapeutic strategies and classification. British Journal Haematology, 127, 3-11. (Pubitemid 39331101)
11. Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E, (2010) Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leukaemia & Lymphoma, 51, 221-227.
12. Shimada M, Johnson RJ, May WS Jr, et al. (2009) A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrology, Dialysis, Transplantation, 24, 2960-2964.
13. Haas M, Ohler L, Watzke H, Bohmig G, Prokesch R, Druml W, (1999) The spectrum of acute renal failure in tumour lysis syndrome. Nephrology, Dialysis, Transplantation, 14, 776-779. (Pubitemid 29106019)
14. Pession A, Melchionda F, Castellini C, (2008) Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics, 2, 129-141.
15. Yim BT, Sims-McCallum RP, Chong PH, (2003) Rasburicase for the treatment and prevention of hyperuricemia. Annals of Pharmacotherapy, 37, 1047-1054. (Pubitemid 36875239)
16. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British Journal Haematology, 149, 578-586.
17. Oldfield V, Perry CM, (2006) Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs, 66, 529-545.
18. Michallet AS, Tartas S, Coiffier B, (2005) Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Supportive Cancer Therapy, 2, 159-166.
19. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr, (2007) Tumor lysis syndrome. Seminars in Thrombosis and Hemostasis, 33, 397-407. (Pubitemid 46878112)
20. Mato AR, Riccio BE, Qin L, et al. (2004) A predictive model for tumor lysis syndrome in acute myelogenous leukemia. Blood, 104, 883.
21. Mato AR, Miltiades AN, Guo M, et al. (2006) Reproducibility of the Penn predictive score of tumor lysis syndrome (PPS-TLS) in acute myelogenous leukemia (AML). Journal of Clinical Oncology, 24, 6577.
22. van den Berg H, Reintsema AM, (2004) Renal tubular damage in rasburicase: risks of alkalinisation. Annals of Oncology, 15, 175-176. (Pubitemid 38139621)
23. Mughal TI, Ejaz AA, Foringer JR, Coiffier B, (2010) An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treatment Reviews, 36, 164-176.
24. Oldfield V, Perry CM, (2006) Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs, 20, 197-199.
25. Pui CH, (2002) Rasburicase: a potent uricolytic agent. Expert Opinion on Pharmacotherapy, 3, 433-442.
26. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A, (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Annals of Hematology, 82, 160-165. (Pubitemid 36700996)
27. Patte C, Sakiroglu C, Ansoborlo S, et al. (2002) Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Annals of Oncology, 13, 789-795. (Pubitemid 34567388)
28. Pui CH, Relling MV, Lascombes F, et al. (1997) Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 11, 1813-1816. (Pubitemid 27485123)
29. Sood AR, Burry LD, Cheng DK, (2007) Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy, 27, 111-121. (Pubitemid 46067966)
30. Goldman SC, Holcenberg JS, Finklestein JZ, et al. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
31. Cortes J, Moore JO, Maziarz RT, et al. (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. Journal of Clinical Oncology, 28, 4207-4213.
32. Kikuchi A, Kigasawa H, Tsurusawa M, et al. (2009) A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. International Journal of Hematology, 90, 492-500.
33. Coiffier B, Mounier N, Bologna S, et al. (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. Journal of Clinical Oncology, 21, 4402-4406. (Pubitemid 46621817)
34. Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F, (1998) Advances in the management of malignancy-associated hyperuricaemia. British Journal of Cancer, 77 (Suppl. 4), 18-20.
35. Pession A, Barbieri E, Santoro N, Paolucci P, Porta F, Locatelli F, (2005) Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. Haematologica, 90, 141-142. (Pubitemid 40193772)
36. Pui CH, Mahmoud HH, Wiley JM, et al. (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. Journal of Clinical Oncology, 19, 697-704. (Pubitemid 32119083)
37. Renyi I, Bardi E, Udvardi E, et al. (2007) Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathology Oncology Research, 13, 57-62. (Pubitemid 46883548)
38. Wang LY, Shih LY, Chang H, et al. (2006) Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematologica, 115, 35-38. (Pubitemid 43130430)
39. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H,. (2003) Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer, 98, 1048-1054. (Pubitemid 37022107)
40. Jeha S, Kantarjian H, Irwin D, et al. (2005) Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia, 19, 34-38. (Pubitemid 40090073)
41. Shin HY, Kang HJ, Park ES, et al. (2006) Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatric Blood & Cancer, 46, 439-445. (Pubitemid 43334649)
42. Cheuk DK, Chiang AK, Chan GC, Ha SY, (2010) Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database of Systematic Reviews, Issue 6, CD006945.
43. Feusner JH, Ritchey AK, Cohn SL, Billett AL, (2008) Management of tumor lysis syndrome: need for evidence-based guidelines. Journal of Clinical Oncology, 26, 5657-5658. Author reply 5658-9.
44. Zaidi SZ, Aljurf M, (2004) Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? Journal of Clinical Oncology, 22, 3430-3431. Author reply 3431-2.
45. Darmon M, Guichard I, Vincent F, (2011) Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. Journal of Clinical Oncology, 29, e67-e68.
46. Tosi P, Barosi G, Lazzaro C, et al. (2008) Consensus conference on the management of tumor lysis syndrome. Haematologica, 93, 1877-1885.
47. Schiffer CA, (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. New England Journal of Medicine, 357, 258-265. (Pubitemid 47080390)
48. Kantarjian H, Shah NP, Hochhaus A, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362, 2260-2270.
49. Saglio G, Kim DW, Issaragrisil S, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362, 2251-2259.
50. Ali R, Ozkalemkas F, Ozkan A, et al. (2007) Tumour lysis syndrome with acute renal failure during imatinib therapy. Leukemia Research, 31, 573-574. (Pubitemid 46198931)
51. Al-Kali A, Farooq S, Tfayli A, (2009) Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. Journal of Clinical Pharmacy and Therapeutics, 34, 607-610.
52. Chang H, Shih LY, (2008) Imatinib-induced tumor lysis syndrome: report of a case and review of the literature. Chang Gung Medical Journal, 31, 510-514.
53. Dann EJ, Fineman R, Rowe JM, (2002) Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 354-355. (Pubitemid 34032634)
54. Lang I, Hitre E, Godeny M, (2002) Rapid clinical improvement and tumor shrinkage following STI571 (Glivec) therapy in a young patient with advanced liver metastases of resected jejunal gastrointestinal stromal tumor (GIST). Program/Proceedings/American Society of Clinical Oncology, 21, Abstract #2383.
55. Keane C, Henden A, Bird R, (2009) Catastrophic tumour lysis syndrome following single dose of imatinib. European Journal of Haematology, 82, 244-245.
56. Kitiyakara C, Atichartakarn V, (2002) Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrology, Dialysis, Transplantation, 17, 685-687. (Pubitemid 34308834)
57. Pinder EM, Atwal GS, Ayantunde AA, Khan S, Sokal M, McCulloch T, Parsons SL,. (2007) Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with Glivec (Imatinib Mesylate, Gleevec, STI571). Sarcoma, 2007:82012.
58. Vora A, Bhutani M, Sharma A, Raina V, (2002) Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Annals of Oncology, 13, 1833-1834. (Pubitemid 35439467)
59. Druker BJ, Sawyers CL, Kantarjian H, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042. (Pubitemid 32267973)
60. Sonmez M, Ovali E, Omay SB, (2008) Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. Journal of Clinical Pharmacy and Therapeutics, 33, 91-92.
61. Sawyers CL, Shah NP, Kantarjian HM, et al. (2005) A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase Chronic Myeloid Leukemia (CML): results from CA180002. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 23 (16S, Part I of II), Abstract #6520.
62. Rousselot P, Cayuela JM, Hayette S, et al. (2010) Dasatinib (Sprycel) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Blood (ASH Annual Meeting Abstracts), 116, Abstract #172.
63. Kim A, Balis FM, Widemann BC, (2009) Sorafenib and sunitinib. Oncologist, 14, 800-805.
64. Huang WS, Yang CH, (2009) Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World Journal of Gastroenterology, 15, 4464-4466.
65. Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B, (2010) Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Investigational New Drugs, 28, 690-693.
66. Nicholaou T, Wong R, Davis ID, (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet, 369, 1923-1924. (Pubitemid 46874569)
67. Saylor PJ, Reid TR, (2007) Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. Journal of Clinical Oncology, 25, 3544-3546. (Pubitemid 47310894)
68. Shiozawa K, Watanabe M, Takenaka H, Nagai H, Ishii K, Sakai K, Sumino Y,. (2010) Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepato-Gastroenterology, 57, 688-690.
69. Foran JM, Ravandi F, O'Brien SM, et al. (2008) Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. Journal of Clinical Oncology, 26 (May 20 Suppl.), Abstract #2518.
70. Moore AS, Blagg J, Linardopoulos S, Pearson AD, (2010) Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia, 24, 671-678.
71. Kantarjian HM, Cortes J, le Coutre P, et al. (2007) A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood (ASH Annual Meeting Abstracts) 110, Abstract #469.
72. Keating GM, (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70, 1445-1476.
73. Abou Mourad Y, Taher A, Shamseddine A, (2003) Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. The Hematology Journal, 4, 222-224. (Pubitemid 36789978)
74. Francescone SA, Murphy B, Fallon JT, Hammond K, Pinney S, (2009) Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplantation Proceedings, 41, 1946-1948.
75. Jabr FI, (2005) Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. International Journal of Hematology, 82, 312-314. (Pubitemid 43329742)
76. Jensen M, Winkler U, Manzke O, Diehl V, Engert A, (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Annals of Hematology, 77, 89-91. (Pubitemid 28425183)
77. Otrock ZK, Hatoum HA, Salem ZM, (2008) Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma. Internal and Emergency Medicine, 3, 161-163.
78. Yang H, Rosove MH, Figlin RA, (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. American Journal of Hematology, 62, 247-250.
79. Byrd JC, Waselenko JK, Maneatis TJ, et al. (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology, 17, 791-795. (Pubitemid 29109307)
80. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE, (2001) Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leukaemia & Lymphoma, 42, 1329-1337. (Pubitemid 34082922)
81. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S, (2010) Cetuximab: from bench to bedside. Current Cancer Drug Targets, 10, 80-95.
82. Krishnan G, D'Silva K, Al-Janadi A, (2008) Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. Journal of Clinical Oncology, 26, 2406-2408.
83. Anderson S, Files J, (2002) Tumor lysis syndrome secondary to Gemtuzumab Ozogamicin in a patient with acute myelogenous leukemia. Journal of the Mississippi State Medical Association, 43, 105-106.
84. Minasian LM, Szatrowski TP, Rosenblum M, et al. (1994) Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood, 83, 56-64.
85. Agura E, Niesvizky R, Matous J, et al. (2009) Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase Ib study. Blood (ASH Annual Meeting Abstracts) 114, Abstract #2870.
86. Casale DA, Bartlett NL, Hurd DD, et al. (2006) A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia. Blood (ASH Annual Meeting Abstracts), 108, Abstract #2727.
87. Raza A, Jurcic JG, Roboz GJ, et al. (2007) Complete remissions observed in acute myeloid leukemia following prolonged exposure to SGN-33 (lintuzumab), a humanized monoclonal antibody targeting CD33. Blood (ASH Annual Meeting Abstracts), 110, Abstract #159.
88. Salles G, Morschhauser F, Lamy T, et al. (2009) Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ Non-Hodgkin Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts), 114, Abstract #1704.
89. Welt S, Ritter G, Cohen L, et al. (1997) Phase I study of humanized A33 (huA33) antibody in patients with advanced colorectal cancer. ASCO Annual Meeting, Abstract #1563.
90. Li S, Gill N, Lentzsch S, (2010) Recent advances of IMiDs in cancer therapy. Current Opinion in Oncology, 22, 579-585.
91. Cany L, Fitoussi O, Boiron JM, Marit G, (2002) Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. Journal of Clinical Oncology, 20, 2212. (Pubitemid 34408815)
92. Fuente N, Mane JM, Barcelo R, Munoz A, Perez-Hoyos T, Lopez-Vivanco G, (2004) Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Annals of Oncology, 15, 537. (Pubitemid 38444562)
93. Huston A, Brown J, Roodman GD, (2006) Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Experimental Hematology, 34, 1616. (Pubitemid 44839002)
94. Lee CC, Wu YH, Chung SH, Chen WJ, (2006) Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist, 11, 87-88. Author reply 89.
95. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB, (2007) Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 5047. (Pubitemid 350220451)
96. Chanan-Khan A, Miller KC, Musial L, et al. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology, 24, 5343-5349. (Pubitemid 46623164)
97. Ferrajoli A, Lee BN, Schlette EJ, et al. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
98. Andritsos LA, Johnson AJ, Lozanski G, et al. (2008) Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 26, 2519-2525.
99. Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K, (2008) Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 26, 4851-4852. Author reply 4852-3.
100. Chanan-Khan A, Miller KC, Lawrence D, et al. (2010) Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer doi:.
101. Ferrajoli A, Badoux X, O'Brien S, et al. (2010) The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 116, Abstract #1395.
102. Dutia M, DeRoock I, Chee K, O'donnell R, Quirch C, Reed-Pease C, Tuscano J,. (2009) R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts), 114, Abstract #1679.
103. Yang H, Zonder JA, Dou QP, (2009) Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opinion on Investigational Drugs, 18, 957-971.
104. Sezer O, Vesole DH, Singhal S, et al. (2006) Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clinical Lymphoma & Myeloma, 7, 233-235. (Pubitemid 44823809)
105. Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G,. (1999) Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. British Journal Haematology, 105, 938-941. (Pubitemid 29309099)
106. Chim CS, (2008) Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome. Cancer Chemotherapy and Pharmacology, 62, 181-182. (Pubitemid 351537845)
107. Furtado M, Rule S, (2008) Bortezomib-associated tumor lysis syndrome in multiple myeloma. Leukaemia & Lymphoma, 49, 2380-2382.
108. Kenealy MK, Prince HM, Honemann D, (2006) Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy, 26, 1205-1206. Discussion 1206. (Pubitemid 44167834)
109. Jaskiewicz AD, Herrington JD, Wong L, (2005) Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy, 25, 1820-1825. (Pubitemid 41790105)
110. Terpos E, Politou M, Rahemtulla A, (2004) Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Journal of Cancer Research and Clinical Oncology, 130, 623-625. (Pubitemid 39371332)
111. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC, (2005) Proteasome inhibition as a novel therapeutic target in human cancer. Journal of Clinical Oncology, 23, 630-639. (Pubitemid 46224241)
112. Berenson JR, Yang HH, Vescio RA, et al. (2008) Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology, 87, 623-631.
113. Chen SL, Jiang B, Qiu LG, Yu L, Zhong YP, Gao W, (2010) Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. Anatomical Record (Hoboken, N.J.: 2007), 293, 1679-1684.
114. Iida S, Mukai HY, Ohyashiki K, et al. (2008) Post-marketing surveillance of bortezomib treatment for Multiple Myeloma (MM) in Japan: results of interim analysis by the velcade Japan proper use Guideline Committee. Blood (ASH Annual Meeting Abstracts), 112, Abstract #5198.
115. Vij R, Wang M, Orlowski R, et al. (2008) Initial results of PX-171-004, an open-label, single-arm, phase II study of Carfilzomib (CFZ) in patients with relapsed myeloma. Blood (ASH Annual Meeting Abstracts), 112, Abstract #865.
116. Shapiro GI, (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology, 24, 1770-1783. (Pubitemid 46628473)
117. Lin TS, Ruppert AS, Johnson AJ, et al. (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. Journal of Clinical Oncology, 27, 6012-6018.
118. Karp JE, Blackford A, Smith BD, et al. (2010) Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research, 34, 877-882.
119. Lin TS, Blum KA, Fischer DB, et al. (2010) Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. Journal of Clinical Oncology, 28, 418-423.
120. Byrd JC, Lin TS, Dalton JT, et al. (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109, 399-404. (Pubitemid 46105932)
121. Phelps MA, Lin TS, Johnson AJ, et al. (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 113, 2637-2645.
122. Blum W, Phelps MA, Klisovic RB, et al. (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica, 95, 1098-1105.
123. Karp JE, Smith BD, Resar LS, et al. (2011) Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 117, 3302-3310.
124. Tong WG, Chen R, Plunkett W, et al. (2010) Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology, 28, 3015-3022.
125. Blum KA, Jones JA, Andritsos L, et al. (2010) Phase 1 trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 116, Abstract #2472.
126. Flynn JM, Jones JA, Andritsos L, et al. (2010) Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration. Blood (ASH Annual Meeting Abstracts), 116, Abstract #1396.
127. Gojo I, Walker A, Cooper M, et al. (2010) Phase II study of the Cyclin-Dependent Kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced acute leukemias. Blood (ASH Annual Meeting Abstracts), 116, Abstract #3287.
128. Piekarz RL, Bates SE, (2009) Epigenetic modifiers: basic understanding and clinical development. Clinical Cancer Research, 15, 3918-3926.
129. Kim Y, Whittaker S, Demierre MF, et al. (2008) Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study. Blood, 112, 103-104.
130. Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P,. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology, 81, 170-176.
131. Kalff A, Shortt J, Farr J, McLennan R, Lui A, Scott J, Spencer A,. (2008) Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia. Haematologica, 93, e16-e17.
132. Cheson BD, (2007) Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management, 3, 855-870. (Pubitemid 350162084)
133. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR, (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 7697-7702. (Pubitemid 46291834)
134. Chanan-Khan AA, Mavromatis B, Rai KR, Casey P, Novick S, Itri LM, (2004) A pilot study of genasense (oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 104, Abstract #4827.
135. O'Brien S, Moore JO, Boyd TE, et al. (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 1114-1120. (Pubitemid 46596764)
136. Jolivet J, Dean E, Ward TH, et al. (2008) A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. Journal of Clinical Oncology, 26 (May 20 Suppl.), Abstract #3541.
137. Beatson GT, (1899) On the etiology of cancer, with a note of some experiments. British Medical Journal, 1, 399-400.
138. Cech P, Block JB, Cone LA, Stone R, (1986) Tumor lysis syndrome after tamoxifen flare. New England Journal of Medicine, 315, 263-264. (Pubitemid 16097136)
139. Plotkin D, Lechner JJ, Jung WE, Rosen PJ, (1978) Tamoxifen flare in advanced breast cancer. JAMA, 240, 2644-2646. (Pubitemid 9100750)
140. Zigrossi P, Brustia M, Bobbio F, Campanini M, (2001) Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Annali Italiani di Medicina Interna, 16, 112-117.
141. Tanvetyanon T, Choudhury AM, (2004) Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. Journal of Urology, 171, 1627. (Pubitemid 38365439)
142. Gold JE, Malamud SC, LaRosa F, Osband ME, (1993) Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. American Journal of Hematology, 44, 42-47. (Pubitemid 23245059)
143. Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I, (2005) Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma. Medical Oncology, 22, 203-206. (Pubitemid 41003455)
144. Warrell RP Jr, Coonley CJ, Gee TS, (1985) Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. Journal of Clinical Oncology, 3, 617-621. (Pubitemid 15119231)
145. Quintas-Cardama A, Kantarjian H, Cortes J, (2009) Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer, 115, 5382-5393.
146. Patterson DM, Charnley N, Saleem A, et al. (2008) Phase I evaluation of vascular disrupting agent OXi4503. Journal of Clinical Oncology, 26 (May 20 Suppl.), Abstract #3551.
147. Horwitz SM, Duvic M, Kim Y, et al. (2008) Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose-finding trial. Blood, 112, 556-557, Abstract 1569.
148. O'Connor OA, Pro B, Pinter-Brown L, et al. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of Clinical Oncology, 29, 1182-1189.
149. Arnold TM, Reuter JP, Delman BS, Shanholtz CB, (2004) Use of single-dose rasburicase in an obese female. Annals of Pharmacotherapy, 38, 1428-1431. (Pubitemid 39100196)
150. Campara M, Shord SS, Haaf CM, (2009) Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. Journal of Clinical Pharmacy and Therapeutics, 34, 207-213.
151. Giraldez M, Puto K, (2010) A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. European Journal of Haematology, 85, 177-179.
152. Ho VQ, Wetzstein GA, Patterson SG, Bradbury R, (2006) Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome. Supportive Cancer Therapy, 3, 178-182. (Pubitemid 44022756)
153. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D, (2008) Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. European Journal of Haematology, 80, 331-336. (Pubitemid 351347575)
154. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M, (2006) Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy, 26, 242-247. (Pubitemid 43201871)
155. Knoebel R, Lo M, Crank C, (2010) Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. Journal of Oncology Pharmacy Practice doi:.
156. Lee AC, Li CH, So KT, Chan R, (2003) Treatment of impending tumor lysis with single-dose rasburicase. Annals of Pharmacotherapy, 37, 1614-1617. (Pubitemid 37315101)
157. Liu CY, Sims-McCallum RP, Schiffer CA, (2005) A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leukemia Research, 29, 463-465. (Pubitemid 40255822)
158. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD, (2006) Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy, 26, 806-812. (Pubitemid 43807632)
159. Reeves DJ, Bestul DJ, (2008) Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy, 28, 685-690. (Pubitemid 351975371)
160. Tarella C, Bono D, Zanni M, Ricca I, Caracciolo D, (2005) Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia. Contributions to Nephrology, 147, 93-104. (Pubitemid 43264988)
161. Trifilio SM, Pi J, Zook J, et al. (2010) Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplantation doi:.
162. Vines AN, Shanholtz CB, Thompson JL, (2010) Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Annals of Pharmacotherapy, 44, 1529-1537.
163. Yim B, Navaleza A, Haidau A, et al. (2010) Single 4.5 mg dose of rasburicase for tumor lysis syndrome in adults. Blood (ASH Annual Meeting Abstracts), 116, Abstract #1779.
164. Vadhan-Raj S, Fayad L, Fanale M, et al. (2009) Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood, 114, 48-49.
165. Annemans L, Moeremans K, Lamotte M, et al. (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leukaemia & Lymphoma, 44, 77-83. (Pubitemid 36113832)
166. Annemans L, Moeremans K, Lamotte M, et al. (2003) Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Supportive Care in Cancer, 11, 249-257. (Pubitemid 36723571)
167. Eaddy M, Seal B, Tangirala M, Davies EH, O'Day K, (2010) Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. American Journal of Health System Pharmacy, 67, 2110-2114.
168. Eaddy M, O'Day K, Tangirala KM, Seal B, (2009) The economic implications of rasburicase treatment in adult tumor lysis syndrome patients. Journal of Clinical Oncology, 27 (Suppl.), Abstract #e17503.
169. Kennedy LD, Ajiboye VO, (2010) Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome. Journal of Oncology Pharmacy Practice, 16, 205-213.
170. El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A, (2011) Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. American Journal of Emergency Medicine doi:.
171. Zhang Z, Fiorino A, (2009) Pharmacokinetics of intravenous Uricase-PEG 20, a drug for managing hyperuricemia in tumor lysis syndrome. Blood, 114, 1200.
172. Khan BA, Deel C, Hellman RN, (2006) Tumor lysis syndrome associated with reduced immunosuppression in a lung transplant recipient. Mayo Clinic Proceedings, 81, 1397-1399. (Pubitemid 44484979)
173. Agrawal AK, Feusner JH, (2011) Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia? British Journal Haematology, 153, 275-277.